



## SCIENTIFIC PROGRAM

(September 15, 2025)

(The Current Sessions and Presentations are in Eastern Standard Time and Subject to Change)

### MONDAY, SEPTEMBER 15, 2025

- 8:00AM** **WELCOME AND INTRODUCTION**  
Faina Shtern, MD, President and CEO, AdMeTech Foundation
- 8:15AM** **SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION**
- Moderators:**
- Peter Albers, MD, Chairman, Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf and Division Head, Division of Personalized Early Detection of Prostate Cancer at the German Cancer Research Center (DKFZ), Heidelberg University, Germany
- Sigrid Carlsson, MD, PhD, MPH, Division Head, Clinical Epidemiology of Early Cancer Detection, DKFZ, Heidelberg University, Germany
- 8:30AM** **Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening**
- 8:30AM** *Topic 1A: Advancing Risk-Stratified Screening and Early Detection:* Sigrid Carlsson, MD, PhD, MPH
- 8:40AM** Q & A
- 8:42AM** *Topic 1B: Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50):* Peter Albers, MD
- 8:52AM** Q & A
- 8:54AM** *Topic 1C: Update on PRAISE-U Project – European Union Initiative in PC Screening:* Monique Roobol, PhD, Professor of Decision Making in Urology and the Head of the Scientific Research Office, Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands
- 9:04AM** *Topic 1D: Update on Göteborg-2 Trial: PSA Screening Followed by MRI:* Jonas Hugosson, MD, Professor, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden
- 9:14AM** *Topic 1E: Update on PROSCREEN: A Randomized Population-Based Screening Trial Combining PSA, Kallikrein Panel and MRI:* Anssi Auvinen, MD, PhD, Professor and Head, Department of Epidemiology, Tampere University, Finland
- 9:24AM** Q & A
- 9:26AM** *Topic 1F: Organized Prostate Testing (OPT) in Sweden:* Anders Bjartell, MD, PhD, FEBU, Professor in Urology, Department of Translational Medicine, Lund University; and Senior Consultant, Skane University Hospital, Sweden
- 9:36AM** Q & A
- 9:38AM** *Topic 1G: TRANSFORM - National UK Trial of Prostate Cancer Screening:* Rhian Gabe, PhD, Professor of Biostatistics and Clinical Trials, Director of Barts Clinical Trials Units, Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom

<b>9:48AM</b>	Q & A
<b>9:50AM-10:10AM</b>	<i>Panel Discussion: “Smart” Prostate Cancer Screening</i>
<b>10:10AM-10:30AM</b>	<b>COFFEE BREAK</b>
<b>10:30AM</b>	<b>SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION</b>
	<b>Moderators:</b>
	Preston Sprenkle, MD, Associate Professor of Surgery, Yale University School of Medicine; and Vice Chair, NCCN Prostate Cancer Early Detection Panel
	Clare M. C. Tempany-Afdhal, MB, BAO, BCh, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women’s Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Immediate Past Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization
<b>10:30AM</b>	<b>Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling</b>
<b>10:30AM</b>	<i>Topic 2A: Current and Emerging Liquid Diagnostics</i>
<b>10:30AM</b>	Overview of Liquid Biomarkers: E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Urology Today; and Prostate Cancer Series Editor, Oncology Journal
<b>10:40AM</b>	Q & A
<b>10:42AM</b>	Large-Scale, Prospective, Clinical Validation Study of the Diagnostic Performance of IsoPSA Without and In Combination with Mutli-Parametric MRI for the Detection of High-Grade Prostate Cancer: Mark Stovsky, MD, MBA, FACS, Chief Medical Officer, Cleveland Diagnostics, Inc. Sponsored by Cleveland Diagnostics.
<b>10:48AM</b>	Q & A
<b>10:50AM</b>	<i>Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies</i>
<b>10:50AM</b>	OPTIMUM Trial – A 3-Arm Randomized Controlled Clinical Study Evaluating the Role of Micro-Ultrasound in Men with Clinical Suspicion of Prostate Cancer: Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation.
<b>11:00AM</b>	Q & A
<b>11:02AM</b>	MRI PI-RADS Standardization and Clinical Evaluation: Clare Tempany, MB, BAO, BCh
<b>11:12AM</b>	Q & A
<b>11:14AM</b>	A Calibration tool for ADC Measurements in Prostate Cancer: Xavier Golay, PhD, MS, Honorary Professor of MRI Physics, University College London, UK
<b>11:24AM</b>	Q & A
<b>11:26AM</b>	<i>Topic 2C: State of the Art and Future Directions in Prostate Biopsies</i>
<b>11:26AM</b>	Urologic Perspective: Alastair Lamb, MD, PhD, FRCS, CRUK Advanced Clinician Scientist Fellow, Barts Cancer Institute, Queen Mary University of London; Honorary Consultant Urological Surgeon, Guy’s Hospital; and Visiting Associate Professor, University of Oxford, United Kingdom
<b>11:36AM</b>	Q & A
<b>11:38AM</b>	Radiologic Imaging Perspective: Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University
<b>11:48AM</b>	Q & A

<b>11:50AM</b>	<i>Topic 2D: Should we be preparing for a biopsy-free future?</i> Mark Emberton, MD, Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom
<b>12:00PM</b>	Q & A
<b>12:02PM</b>	<i>Topic 2E: Current and Emerging Data on the Role of PSMA Imaging in Selecting Patients for Biopsies:</i> Lorenzo Bianchi, MD, PhD, Associate Professor, Department of Medical and Surgical Sciences, and Specialist in Urology, IRCCS University Hospital of Bologna, University of Bologna, and Saint'Orsola Policlinic, Bologna, Italy
<b>12:12PM-12:30PM</b>	<i>Panel Discussion: Current and Emerging Diagnostic Tools</i>
<b>12:30PM</b>	<b>Topic 3: Newly Identified Germline Mutations Associated with Prostate Cancer Risk and Aggressiveness:</b> Brian T. Helfand, MD, PhD, Ronald L. Chez Family and Richard Melman Family Endowed Chair in Prostate Cancer, and Clinical Professor, University of Chicago, Pritzker School of Medicine, NorthShore University HealthSystem, Endeavor Health
<b>12:40PM</b>	Q & A
<b>12:42PM</b>	<b>Topic 4: NCCN Guidelines for Early Detection of Prostate Cancer 2025:</b> Preston Sprenkle, MD
<b>12:52PM</b>	Q & A
<b>12:54PM-1:30PM</b>	<b>General Discussion</b> – Moderators and Speakers
<b>1:30PM-3:00PM</b>	<b>LUNCH BREAK</b>
<b>3:00PM</b>	<b>PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT</b>  <b>Moderators:</b>  Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA  Amita Dave, PhD, Vice-Chair, Radiology-Medical Physics Outreach; Deputy Service Chief for Predictive Informatics, and Director of Quantitative Imaging, Department of Radiology, Memorial Sloan Kettering Cancer Center
<b>3:00PM</b>	<i>AI and Big Data: What's Close and What's Far Away?:</i> Paul Boutros, PhD, MBA
<b>3:10PM</b>	Q & A
<b>3:12PM</b>	<i>How Artificial Intelligence and Deep Learning Algorithms Can Help with Prostate MRI:</i> Mukesh Harisinghani, MD, Professor of Radiology, Harvard Medical School; and Director of Body Translational MRI, and Director of the Clinical Discovery Program Center for Molecular Imaging Research, Massachusetts General Hospital, Sponsored by Siemens
<b>3:17PM</b>	<i>Augmented Reality for Prostate Biopsies:</i> Archan Khandekar, Assistant Professor of Clinical Urology, Desai Sethi Urology Institute, Miller School of Medicine, University of Miami
<b>3:27PM</b>	Q & A
<b>3:30PM</b>	<i>Deep Phenotyping of Prostate Cancer via Multi-Model Imaging and AI to Discover High-Risk Phenotypes:</i> Rakesh Shiradkar, PhD, Assistant Professor, BioHealth Informatics, Indiana University
<b>3:40PM</b>	Q & A
<b>3:42PM</b>	<i>Data-Driven Strategies in Prostate Cancer Care:</i> Ilya Gipp, MD, PhD, Chief Medical Officer - Oncology, GE Healthcare, Sponsored by GE Healthcare
<b>4:04PM</b>	Q & A
<b>4:06PM-5:30PM</b>	<i>Panel Discussion: Moderators and Speakers</i>

**TUESDAY, SEPTEMBER 16, 2025**

**8:00AM**      **SESSION II (PART 1). CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER**

**Moderators:**

Alberto Vargas, MD, Professor and Vice Chair, Department of Radiology, New York University

Mohammed Shahait, MD, Assistant Professor of Clinical Urology, Department of Urology, University of California, Irvine

Lalitha K. Shankar, Acting Associate Director, Cancer Imaging Program; and Chief, Clinical Trials Branch, National Cancer Institute, National Institutes of Health

**8:05AM**      **Topic 1: Multiomics for Prostate Cancer**

**8:05AM**      *Topic 1A: Radiologic Perspective: Clinical and Prognostic Implications of Cancer Visibility on Imaging*

**8:05AM**      MRI: Alberto Vargas, MD, Professor and Vice Chair, Department of Radiology, New York University

**8:15AM**      Q & A

**8:17AM**      Molecular Imaging: Professor Michael Hofman, MBBS, FRACP, FAANMS, FICIS, FSNM, FAHMS, GAICD, PET/CT Head, Cancer Imaging; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProTIC); Peter MacCallum Cancer Centre, Melbourne; and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia

**8:27AM**      Q & A

**8:29AM**      *Topic 1B: Urologic Perspective: Genomics and Natural History of MRI Invisible vs Visible Cancers: Laurence Klotz, MD*

**8:39AM**      Q & A

**8:41AM**      *Topic 1C: Molecular and Multi-Modality Imaging for Visualization and Staging of the Initial and Recurrent Disease*

**8:41AM**      Micro-Ultrasound vs. MRI for Biopsy Decision Making and Active Surveillance: Adam Kinnaird, MD, PhD, FRCSC, Frank and Carla Sojonyk Chair in Prostate Cancer Research; Assistant Professor, Division of Urology, Department of Surgery; and Adjunct Assistant Professor, Department of Oncology, University of Alberta, Canada

**8:51AM**      Q & A

**8:53AM**      PSMA Imaging-Guided Salvage Radiotherapy in Patients with Biochemical Recurrence after Radical Prostatectomy- Emerging Five-Year Outcomes: Andrea Di Giorgio, MD, Nuclear Medicine Unit - University of Bologna, and University of Bologna Medical Center, Italy

**9:03AM**      Q & A

**9:05AM**      *Topic 1D: Gleason Pattern Quantification as a Replacement for Gleason Scoring: Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center*

**9:15AM**      Q & A

**9:17AM**      *Topic 1E: Novel and Emerging Pathological Factors in Localized and Recurrent Prostate Cancer: Gladell P. Paner, MD, Professor of Pathology and Surgery (Urology), and Director of Genitourinary Pathology Service, University of Chicago*

**9:27AM**      Q & A

**9:29AM**      *Topic 1F: A Deeper Look into the Favorable Intermediate-Risk Patients: Deepika Bhagwat BS, MD, BCMAS, Senior Medical Science Liaison for Mdxhealth, Sponsored by MDx Health*

**9:35AM**      *Topic 1G: Integration of MRI with Histology, Genomics, and Proteomics: Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA*

**9:45AM**      Q & A

**9:47AM-10:00AM**      *Panel Discussion: Multiomics – Moderators and Speakers*

10:00AM-  
10:30AM

**COFFEE BREAK**

10:30AM

**SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER**

**Moderators:**

Carlos A. Buchpiguel, MD, PhD, Director of Molecular Imaging and Nuclear Medicine Division; and Full Professor, Department of Radiology and Oncology, São Paulo University School of Medicine, São Paulo -SP, Brazil

Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF

Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign

10:30AM

**Topic 2: Year in Review - Emerging Advances in Diagnosis and Treatment:** Matthew Cooperberg, MD, MPH

10:40AM

Q & A

10:42AM

**Topic 3: Next-Generation Risk Stratification:** Alastair Lamb, MD, PhD, FRCS

10:52AM

Q & A

10:54AM

**Topic 4: Old School, New Insight: Histomorphology in the Modern Biomarker Era of Risk Stratification of Prostate Cancer:** Jane Nguyen, MD, PhD, Assistant Professor of Pathology at the Case Western Reserve University/Lerner College of Medicine; Director of Genitourinary Pathology; Staff Pathologist in the Diagnostics Institute, Department of Pathology and Laboratory Medicine at the Cleveland Clinic

11:04AM

Q & A

11:06AM

**Topic 5: Human-AI Interaction in Prostate Cancer Detection and Diagnosis: Ways to Team Up:** Evis Sala, MD, PhD, FRCR, FRCP, Professor of Radiology & Director of Radiology Training Program, Università Cattolica del Sacro Cuore, Rome, Italy

11:16AM

Q & A

11:18AM

**Topic 6: The Future of PSMA PET Imaging:**

Ashley E. Ross, MD, PhD, Associate Professor of Urology and Clinical Director, Polsky Urologic Oncology Center, Northwestern Feinberg School of Medicine. Sponsored by Blue Earth Diagnostics.

11:28AM

**Topic 7: Integration of Precision Diagnosis and Precision Treatment**

11:28AM

*Topic 7A: Integrated Diagnostics (Radiogenomics) for Active Surveillance, Surgical and Radiation Treatment:* Sanoj Punnen, MD, MAS, MBA, Professor of Urology, and Vice Chair of Research, Desai Sethi Urology Institute; and Assistant Director of Clinical Research and Cancer Control Research Program Co-Lead, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine

11:38AM

Q & A

11:40AM

*Topic 7B: Image-Guided, Minimally-Invasive Focal Treatment: Emerging Role in Patient Management:* Bruno Nahar, MD, Associate Professor of Urologic Oncology, Eric and Elizabeth Feder Endowed Chair in Urologic Oncology Research, Desai Sethi Urology Institute, University of Miami Miller School of Medicine

11:50AM

Q & A

11:52AM

*Topic 7C: Radiation Treatment:* Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University

12:02PM

**Topic 8: Optimal Management of Patients Presenting with Locally Advanced Prostate Cancer in 2025:** Raja B. Khauli, MD

12:12PM

Q & A

12:14PM

**Topic 9: Recurrent Disease**

12:14PM

*Topic 9A: Principles of Focal Salvage Treatment for Radiorecurrent Prostate Cancer – Is it Feasible?:* Giancarlo Marra, MD, Consultant Urologist and Assistant Professor, Division of Urology, AOU Città Della Salute e Della Scienza and University of Turin, Italy

<b>12:24PM</b>	Q & A
<b>12:26PM</b>	<i>Topic 9B: Determining the Benefit of Therapy for Biochemically Recurrent Prostate Cancer:</i> David Einstein, MD, Assistant Professor, Harvard Medical School, and Attending Physician, Beth Israel Deaconess Medical Center Genitourinary Medical Oncology Program
<b>12:36PM</b>	Q & A
<b>12:38PM</b>	<i>Topic 9C: Clinical Role of PET/MRI in Biochemical Recurrence:</i> Hong Song, MD, PhD, Assistant Professor, Nuclear Medicine and Radiology, Stanford University
<b>12:48PM</b>	Q & A
<b>12:50PM-1:15PM</b>	<i>Panel Discussion: Integration of Precision Diagnosis and Treatment</i>
<b>1:15PM-2:15PM</b>	<b>LUNCH BREAK</b>
<b>2:15PM</b>	<b>SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER</b>
	<b>Moderators:</b>
	Steven Eric Finkelstein, MD, DABR, FACRO, National Director of the Center of Advanced Radiation Excellence (CARE) and Director, Radiation Oncology Research, Associated Medical Professionals / US Urology, Syracuse, NY; and Board of Chancellors and Chair of Education Committee, American College of Radiation Oncology (ACRO)
	Katherine Ferrara, PhD, Professor and Division Chief, Molecular Imaging Program, Stanford University
	Raluca Mititelu, MD, PhD, Lecturer, University of Medicine and Pharmacy Carol Davila Bucharest Clinic of Nuclear Medicine, Central University Emergency Military Hospital Bucharest, Romania
<b>2:16PM</b>	<b>Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease</b>
<b>2:16PM</b>	<i>Topic 1A: NCCN Guidelines for Management of Advanced PC:</i> Marc B. Garnick, MD, Director of Cancer Community Services, BIDMC; Gorman Brothers Professor of Medicine at Harvard Medical School; and Editor-in-Chief, Harvard Medical School Prostate Disease Report
<b>2:26PM</b>	Q & A
<b>2:28PM</b>	<i>Topic 1B: Sequencing of Treatment:</i> Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors
<b>2:38PM</b>	Q & A
<b>2:40PM</b>	<i>Topic 1C: Novel Systemic Treatment: Recent Advances and Future Directions in Targeted Treatment:</i> Daniel P. Petrylak, MD, Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University
<b>2:48PM-3:05PM</b>	<b>COFFEE BREAK</b>
<b>3:05PM</b>	<i>Topic 1D: Immunotherapy:</i> Sandy Srinivas, MD, Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment
<b>3:15PM</b>	Q & A
<b>3:17PM</b>	<i>Topic 1E: Emerging Advances in Precision Radiation Treatment and Immunotherapy – Fireside Chat:</i> Steven E. Finkelstein, MD, and Patrick Soon-Shiong, MD, Executive Chairman and Global Chief Scientific and Medical Officer, ImmunityBio
<b>3:27PM</b>	Q & A
<b>3:29PM-3:50PM</b>	<i>Panel Discussion: Standard and Emerging Treatment</i>



<b>3:50PM</b>	<b>Topic 2: Molecular Imaging and Theranostics</b>
<b>3:50PM</b>	<i>Topic 2A: Radiopharmaceutical Design and Molecular Imaging:</i> Katherine Ferrara, PhD
<b>4:00PM</b>	Q & A
<b>4:02PM</b>	<i>Topic 2B: Radiologic Perspective on Integration of Molecular Imaging and Treatment:</i> Andrei Iagaru, MD, Professor of Radiology and Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program, Stanford University
<b>4:12PM</b>	Q & A
<b>4:14PM</b>	<i>Topic 2C: PSMA-Targeted Therapy - Clonal Heterogeneity, Neuroendocrine Differentiation, and Finding the Right Sequence of Systemic Treatment:</i> Vikas Prasad, MD, PhD, Associate Professor of Radiology, Director of Clinical Theranostics, Center for Clinical Theranostics Research, Division of Nuclear Medicine, Mallinckrodt Institute of Radiology; and Co-Chair, Theranostics Program, Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri
<b>4:24PM</b>	Q & A
<b>4:26PM</b>	<i>Topic 2D: Medical Oncology Perspective on Integration of Molecular Imaging and Treatment:</i> Diogo Assed Bastos, MD, Genitourinary oncologist, Hospital Sirio-Libanês, São Paulo, Brazil. Member of the Latin American Cooperativa Oncology Group (LACOG)
<b>4:36PM</b>	Q & A
<b>4:38PM</b>	<i>Topic 2E: Strategies to Drive Broader Impact of Emerging Radioligand Therapy for Prostate Cancer:</i> Ilya Gipp, MD, PhD
<b>4:48PM</b>	Q & A
<b>4:50PM-5:00PM</b>	<i>Panel Discussion: Molecular Imaging and Theranostics</i>
<b>5:00PM-6:00PM</b>	<b>General Discussion: Speakers, Moderators</b>

### **WEDNESDAY, SEPTEMBER 17, 2025**

<b>8:00AM</b>	<b>SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring &amp; Outcomes</b>
	<b>Moderators:</b>
	David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York
	Giovanni Lughezzani, MD, Staff Physician, Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (MI), and Associate Professor, Humanitas University, Milan, Italy
	Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
	Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
	Stenio Zequi, MD, MSc, PhD, Head of Referral Center for Urological Tumors, A.C. Camargo Cancer Center, Brazil
<b>8:00AM</b>	<b>Topic 1: Focal Therapy for Localized Prostate Cancer: Why Hasn't it Become the Standard of Care?:</b> Rafael Sanchez-Salas, MD, Associate Professor of Surgery and Attending Surgeon, Division of Urology, Department of Surgery, McGill University, Canada
<b>8:10AM</b>	Q & A
<b>8:12AM</b>	<b>Topic 2: Patient Selection for Targeted Treatment - Imaging Perspective</b>
<b>8:12AM</b>	<i>Topic 2A: Multiomics and Patient Selection:</i> John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
<b>8:22AM</b>	Q & A

8:24AM	<i>Topic 2B: Quantitative MRI Reading, AI Derived Algorithms for ECE/BCR, and AI Use in MRI Directed Treatment of Prostate Cancer:</i> Victoria Bird, MD, President and Founder of Urologic Integrated Care, Gainesville, FLA; Staff Urologic Surgeon, HCA Florida North Florida Hospital; CEO, Urology Division, Research Group, National Medical Association; and Former Affiliate Professor of Engineering, Biomedical Engineering, College of Engineering, and Former Assistant Professor, Department of Urology, College of Medicine, University of Florida
8:34AM	Q & A
8:36AM	<i>Topic 2C: Energy Sources and Emerging Clinical Indications:</i> Jurgen Futterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen; and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands
8:46AM	Q & A
8:48AM	<b>Topic 3: Patient Selection for Targeted Treatment – Urologic Perspective:</b> Geoffrey Sonn, MD, Associate Professor of Urology and Radiology, Stanford University School of Medicine
8:58AM	Q & A
9:00AM	<b>Topic 4: Micro-Ultrasound and Irreversible Electroporation (IRE) for Treatment of Prostate Cancer:</b> Xiaosong Meng, MD, PhD, Assistant Professor and Dedman Family Scholar in Clinical Care, Department of Urology, University of Texas Southwestern Medical Center. Sponsored by Exact Imaging
9:12AM	<b>Topic 5: The Evolution of TULSA-PRO: From Concept to AI-Powered, MRI-Guided Precision Prostate Treatment:</b> Peter Pinto, MD, National Institutes of Health, Director of the Urologic Oncology Fellowship Program at the National Cancer Institute, Sponsored by Profound Medical
9:18AM	Q & A
9:20AM	<b>Topic 6: Focal Treatment - Recurrences and Management:</b> Abhinav Sidana, MD, MPH, Associate Professor of Surgery, Director of Focal Therapy, University of Chicago
9:30AM	Q & A
9:32AM-9:45AM	<i>Panel Discussion</i>
9:45AM-10:00AM	<b>COFFEE BREAK</b>
10:00AM	<b>Topic 7: Addressing Fundamental Challenges in Clinical Evaluation, Acceptance and Adoption of Image-Targeted Treatment- Perspective from the AdMeTech Foundation's International Working Group</b>
10:00AM	<i>Review and Update – Imaging for Improving Post-Ablation Assessment and Developing Short-Term Patient Outcomes:</i> Faina Shtern, MD
10:10AM	<i>Standardized MRI and Molecular Imaging Reporting for Treatment Follow-up:</i> Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University
10:20AM	Q & A
10:22AM	<i>Overview of the Current Approaches to Standardized MRI Reporting:</i> Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of Medical Sciences, University College London, Honorary Consultant Radiologist, University College London Hospitals
10:32AM	<i>University of Toronto Experience - MRI After Focal Treatment:</i> Sangeet Ghai, MD, Professor and Trachtenberg Haque Chair in Image Guided Prostate Therapy Research, Director of Research, Joint Department of Medical Imaging, University Health Network – Mt Sinai Hospital – Women's College Hospital, University of Toronto, Canada
10:42AM	Q & A
10:44AM	<i>A New Scoring System for PSMA Imaging and PSMA/MRI Integration for Patient Evaluation after Focal Treatment: Development and Preliminary Data:</i> Giovanni Lughezzani, MD
10:54AM	Q & A



10:56AM	<b>Panel on MRI Reporting Post Focal Treatment –Rationale, Background, &amp; Recommendations</b>
10:56AM	<i>Leaders:</i> Sangeet Ghai, MD, and Daniel Margolis, MD
11:00AM-11:30AM	<i>Panel Discussion – MRI Reporting:</i> Giovanni Lughezzani, MD; Angela Tong, MD, Clinical Assistant Professor, Abdominal Imaging Section, Departments of Radiology and Urology, NYU, and Sadhna Verma, MD, FSAR, Professor of Radiology, University of Cincinnati College of Medicine
11:30AM	<b>Panel on Molecular Imaging Post Focal Treatment – Rationale, Background, Emerging Data and Next Steps</b>
11:30AM	<i>Leaders –</i> Andrei Iagaru, MD and Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland
11:40AM	<i>Urologic Perspective on Molecular Imaging and Post-Focal Treatment Assessment:</i> Geoffrey Sonn, MD
11:45AM-11:50AM	<i>Emerging Data:</i> Andrea Di Giorgio, MD
11:50AM-12:00PM	<i>Panel Discussion: Molecular Imaging</i>
12:00PM-1:00PM	<b>LUNCH BREAK</b>
1:00PM	<b>KEYNOTE PRESENTATIONS</b>
1:00PM	<b>Precision Care and Health Disparities in Prostate Cancer - Risk Assessment in Black Men:</b> Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health; and Faina Shtern, MD
1:15PM	Q & A
1:20PM	<b>Do We Understand the Prostate Cancer Genome?:</b> Paul Boutros, PhD, MBA
1:35PM	Q & A
1:40PM-2:00PM	<b>PRESENTATION OF WINNING ABSTRACTS</b>
	<b>First Place</b> - <i>Targeted Prostate Health Checks to Address Healthcare Inequalities in Prostate Cancer Diagnoses - Results of a Feasibility Pilot for High-Risk Populations in Northeast London:</i> Prabhakar Rajan, MD, Consultant Urologist, Professor of Urology and Robotic Surgery, and Chair of Urology, Queen Mary University of London, United Kingdom
	<b>Second Place</b> - <i>Seminal Plasma Proteomics for Prostate Cancer Detection and Risk Stratification - A Multicenter Study:</i> Fernanda Orellana, MD, Urologist, Universidade Federal de São Paulo (UNIFESP)
	<b>Third Place</b> - <i>Evaluation of Urinary Prostate Cancer Biomarkers in Predicting Biopsy Outcomes:</i> Paula Robins, PA, Patient Care Navigator, University of California San Diego
	<b>Fourth Place</b> - <i>Financial Toxicity and Distress Among Prostate Cancer Patients in a Single Center in Lebanon - A Cross-Sectional Study:</i> Anthony Mina, MD, MPH, Urology Resident, Holy Spirit University, Kaslik, Lebanon
2:00PM-4:00PM	<b>GENERAL DISCUSSION</b>
4:00PM	<b>ADJOURN</b>